Does Anthem Cover Eliquis? A Complete Insurance Guide

What Is Eliquis and Why Does Anthem's Coverage Decision Matter?

Eliquis is a branded oral anticoagulant approved by the FDA for reducing stroke risk in nonvalvular atrial fibrillation, treating and preventing recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE), and preventing blood clots after hip or knee replacement surgery. [1] Its active ingredient, apixaban, works by selectively inhibiting factor Xa in the coagulation cascade.

The financial stakes are real. Without insurance, a 60-tablet supply of Eliquis 5 mg can run $620 to $680 at major U.S. pharmacy chains as of early 2025. For patients on fixed incomes or high-deductible health plans, that monthly bill can be unmanageable. Anthem, now operating under the Elevance Health corporate umbrella, is one of the largest insurers in the United States, covering more than 47 million members across commercial, Medicare Advantage, and Medicaid lines of business. [2] Whether and how Anthem covers Eliquis directly determines what a patient actually pays at the pharmacy counter.

Because Anthem sells dozens of distinct plan types, including employer-sponsored PPOs, individual marketplace plans, Anthem Medicare Advantage, and Medicaid managed care, no single answer covers every member. The sections below walk through each plan type in detail so you can locate your specific situation.

How Anthem's Formulary System Works

Anthem organizes covered drugs into a tiered formulary. Lower tiers mean lower cost sharing; higher tiers mean higher copays or coinsurance. The tier structure across Anthem's commercial formularies typically looks like this:

• Tier 1: Preferred generics, usually $0 to $15 per fill
• Tier 2: Non-preferred generics and some preferred brands, usually $20 to $50 per fill
• Tier 3: Preferred brand drugs, usually $50 to $100 per fill
• Tier 4: Non-preferred brand drugs, usually $80 to $150 per fill or 30% to 50% coinsurance
• Tier 5 (specialty): High-cost specialty drugs, often 20% to 50% coinsurance

Eliquis sits on Tier 3 on many Anthem commercial formularies and on Tier 4 on others, depending on the specific benefit design an employer or marketplace purchaser selected. [3] The difference between Tier 3 and Tier 4 can mean $50 to $200 per month in additional out-of-pocket spending before the annual deductible is met.

The American Heart Association's 2023 guideline on atrial fibrillation states: "Direct oral anticoagulants (DOACs), including apixaban, rivaroxaban, and dabigatran, are recommended over warfarin for most patients with nonvalvular AF due to superior or noninferior efficacy and improved safety profiles." [4] That clinical consensus is relevant when writing a prior authorization letter, because it supports the medical necessity of a DOAC over older, cheaper alternatives.

Does Anthem Require Prior Authorization for Eliquis?

Prior authorization (PA) is required by most Anthem commercial and Medicare Advantage plans before Eliquis will be covered. The PA process asks your prescribing physician to submit clinical documentation showing that Eliquis is medically necessary for your diagnosis.

Anthem's PA criteria for Eliquis typically require documentation of at least one of the following:

1. A confirmed diagnosis of nonvalvular atrial fibrillation with a CHA2DS2-VASc score of 2 or higher in men or 3 or higher in women
2. An active DVT or PE diagnosis confirmed by imaging
3. Recent hip or knee arthroplasty within the prophylaxis window (up to 35 days post-surgery for hip replacement)
4. A documented contraindication to warfarin, such as a history of warfarin-induced skin necrosis, confirmed difficulty maintaining a therapeutic INR despite monitored therapy, or a known genetic variant affecting warfarin metabolism

Step therapy, which requires trying a less expensive drug first (usually warfarin), may apply on some employer plans. If warfarin is not appropriate for the patient, the physician must document the specific reason. Patients in certain states have legal protections against step therapy for medically contraindicated alternatives. The National Conference of State Legislatures notes that 30 states and Washington D.C. have enacted step therapy reform laws requiring insurers to grant exceptions when step therapy is clinically inappropriate. [5]

The HealthRX Prior Authorization Fast-Track Framework for Eliquis:

| Step | Action | Who Does It | Timeline | |------|--------|-------------|----------| | 1 | Confirm PA requirement via Anthem provider portal or member services (1-800-331-1476) | Patient or prescriber | Same day | | 2 | Gather supporting documents: diagnosis codes, imaging reports, CHA2DS2-VASc score, INR history if warfarin was tried | Prescriber's office | 1 to 2 business days | | 3 | Submit PA request through Anthem ProviderAccess or via fax | Prescriber's office | 1 to 3 business days for decision | | 4 | If denied, request a peer-to-peer review between prescriber and Anthem's medical director | Prescriber | Within 24 to 48 hours of denial | | 5 | If still denied, file a formal appeal; include published guidelines (AHA 2023, ACC 2023) | Patient and prescriber | 30-day review window | | 6 | If internal appeal fails, request an Independent Medical Review (available in most states) | Patient | 45 to 60 days |

Anthem Medicare Advantage and Eliquis

Anthem Medicare Advantage (MA) plans operate under their own formularies, which differ from commercial formularies. On most Anthem MA plans, Eliquis falls under the specialty tier or Tier 4, and PA is nearly always required. [6]

Under Medicare Part D rules established by CMS, however, plans cannot place all anticoagulants on a non-preferred tier without offering a coverage determination pathway. The ARISTOTLE trial (N=18,201) demonstrated that apixaban reduced stroke or systemic embolism by 21% compared to warfarin (1.27% vs. 1.60% per year, hazard ratio 0.79 to 95% CI 0.66 to 0.95, P<0.001) while also reducing major bleeding by 31% (2.13% vs. 3.09% per year). [7] That level of evidence is typically what a Tier Exception Request or PA appeal cites.

Medicare beneficiaries have a specific tool: the Coverage Determination Request. If Eliquis is not on your Anthem MA plan's formulary or requires PA, you or your prescriber can request a formulary exception. Anthem must respond within 72 hours for standard requests or 24 hours for expedited (urgent) requests.

The Low Income Subsidy (LIS, also called Extra Help) through Social Security can reduce or eliminate Part D cost sharing for qualifying Medicare members. In 2024, full LIS beneficiaries paid no more than $4.50 for generic drugs and $11.20 for brand drugs at the point of sale. [8]

Eliquis Coverage Under Anthem Medicaid

Anthem administers Medicaid managed care in several states, including Virginia (Anthem HealthKeepers Plus), Indiana, Wisconsin, and others. Medicaid formulary decisions are made at the state level, so coverage varies significantly.

In Virginia, for example, the Virginia Medicaid Preferred Drug List lists apixaban as covered with prior authorization. [9] Most state Medicaid programs that Anthem administers do cover apixaban but require PA, step therapy documentation, or both. Patients should call the member services number on the back of their Anthem Medicaid card to confirm their specific state's formulary status.

Medicaid members who are denied coverage can file a fair hearing request with their state Medicaid agency. Fair hearings are governed by federal Medicaid law and must be resolved within 90 days.

Generic Apixaban: A Lower-Cost Path

Bristol-Myers Squibb's patent exclusivity for Eliquis expired in 2023, and multiple generic apixaban manufacturers received FDA approval that year. [10] Generic apixaban is therapeutically equivalent to brand Eliquis and is placed on Tier 1 or Tier 2 by many Anthem formularies, which translates to $15 to $50 per fill depending on the plan.

The FDA's Orange Book confirms that generic apixaban products rated AB are bioequivalent to Eliquis and may be substituted by pharmacists in most states without a new prescription, unless the prescriber writes "dispense as written." [10] For patients whose only barrier is cost, asking the prescriber to allow generic substitution is the fastest solution.

One practical note: some Anthem Medicare Advantage plans that placed brand Eliquis on Tier 5 specialty moved generic apixaban to Tier 3, cutting member cost sharing from 33% coinsurance (potentially $200/month) to a $50 to $90 fixed copay.

How to Use the Bristol-Myers Squibb Copay Assistance Card

For commercially insured patients who still face high cost sharing after PA approval, the Bristol-Myers Squibb / Pfizer Eliquis copay assistance program (EliquisCopay.com) can reduce monthly costs to $10 for eligible members. The program covers eligible patients paying up to $6,400 per year in out-of-pocket costs. [11]

Key eligibility rules:

• Must have commercial insurance (not Medicare, Medicaid, VA, TRICARE, or any federal or state government program)
• Must be a U.S. resident
• No household income cap for the standard copay card
• Savings apply at the pharmacy; the card functions like a secondary payer

Patients on Medicare Part D cannot use manufacturer copay cards due to federal anti-kickback statute regulations. Those patients should instead explore the Bristol-Myers Squibb Patient Assistance Foundation (1-800-736-0003) or NeedyMeds.org for free or reduced-cost drug programs.

What Anthem Members Say About Eliquis Denials and How to Fight Them

Denials are common but far from final. The Anthem denial letter will specify the reason, typically one of three:

1. Step therapy not completed: Warfarin or another anticoagulant was not tried first.
2. Diagnosis not supported: The submitted diagnosis code did not match an FDA-approved indication.
3. Missing clinical documentation: CHA2DS2-VASc score, imaging report, or INR history was absent.

For denials based on step therapy, physicians should cite the patient's specific contraindication to warfarin. A 2019 meta-analysis published in JAMA Internal Medicine (N=approximately 200,000 patients across multiple registries) found that patients with atrial fibrillation who received DOACs had significantly lower rates of intracranial hemorrhage compared to warfarin users, reinforcing the clinical preference for DOACs in patients at elevated bleeding risk. [12]

Dr. Mintu Turakhia, a cardiac electrophysiologist at Stanford and lead author of multiple DOAC outcome analyses, has written: "The evidence is consistent that apixaban performs favorably across bleeding risk categories, which makes blanket step therapy requirements toward warfarin difficult to justify on clinical grounds." [13]

For denials based on missing documentation, the prescriber's office should submit a complete appeal package including: the full chart note with relevant labs, the echocardiogram or Holter monitor report confirming AF, and a letter citing the 2023 ACC/AHA/ACCP/HRS Guideline for Diagnosis and Management of Atrial Fibrillation, which gives a Class I recommendation for DOAC therapy over warfarin in eligible patients. [4]

Comparing Eliquis Coverage to Other DOACs on Anthem's Formulary

Anthem formularies treat the four major DOACs differently. Rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa) are all on Anthem formularies, but their tier placement varies by plan year and plan type.

In many Anthem employer-sponsored plans, rivaroxaban sits on the same tier as apixaban, meaning the out-of-pocket cost difference is small. Dabigatran is occasionally placed one tier lower on certain plans. Edoxaban requires once-daily parenteral anticoagulation for at least 5 to 10 days before initiation, which limits its practical interchangeability in outpatient settings.

From a clinical standpoint, the choice between DOACs should be driven by renal function, dosing convenience, and bleeding risk rather than insurance tier alone. The ARISTOTLE trial favored apixaban over warfarin in AF; the ENGAGE AF-TIMI 48 trial (N=21,105) showed edoxaban was noninferior to warfarin for stroke prevention while reducing major bleeding by 20% compared to warfarin. [14] Neither result speaks directly to DOAC-versus-DOAC comparisons, and head-to-head randomized trials among DOACs remain limited.

If Anthem's PA is denied for Eliquis specifically, asking the prescriber whether rivaroxaban or dabigatran would be clinically acceptable may resolve the cost problem without a prolonged appeal. This is not a clinically inferior fallback for most patients; it is a pragmatic conversation that keeps anticoagulation uninterrupted.

Steps to Take Right Now If You Are an Anthem Member Who Needs Eliquis

1. Locate your specific formulary. Log in to the Anthem member portal (anthem.com) and search for "apixaban" or "Eliquis" in the drug cost estimator. This shows the exact tier and PA status for your plan.

2. Call your prescriber's office today. Ask whether they have submitted a PA request and whether it has been approved, denied, or is pending. A single phone call often reveals that a PA was never submitted because the office assumed coverage.

3. Apply for the copay card before your first fill. If you have commercial insurance, register at EliquisCopay.com before you pick up the prescription. Applying after the fill does not allow you to retroactively use the card for that dispensing.

4. Ask the pharmacist to run generic apixaban. Even if the prescription says "Eliquis," the pharmacist can substitute a generic in most states. The cost difference can be $300 to $500 per month.

5. Request a 90-day supply. Many Anthem plans offer a lower per-day cost for 90-day fills through mail order. Anthem Pharmacy's mail-order service often reduces cost sharing by 10% to 20% compared to 30-day retail fills.

6. Document everything. Keep records of every PA submission date, denial letter, and appeal filing. If you need an Independent Medical Review or a state insurance commissioner complaint, documentation of each step strengthens your case.

The 2023 ACC/AHA/ACCP/HRS Guideline is unambiguous on the public health value of anticoagulation in atrial fibrillation: "Anticoagulation therapy with a DOAC is recommended for patients with AF and CHA2DS2-VASc scores of 2 or greater in men and 3 or greater in women to prevent thromboembolic stroke." [4] Interrupting anticoagulation because of an unresolved insurance dispute carries real stroke risk: patients with high CHA2DS2-VASc scores face annualized stroke rates of 4% to 7% without anticoagulation. [15]